These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 30195742)

  • 1. Evaluation of a few discrete clinical markers may predict categorization of actively symptomatic non-acute schizophrenia patients as treatment resistant or responders: A study by ROC curve analysis and multivariate analyses.
    Iasevoli F; Avagliano C; Altavilla B; Barone A; Ciccarelli M; D'Ambrosio L; Notar Francesco D; Razzino E; Fornaro M; de Bartolomeis A
    Psychiatry Res; 2018 Nov; 269():481-493. PubMed ID: 30195742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment resistant schizophrenia and neurological soft signs may converge on the same pathology: Evidence from explanatory analysis on clinical, psychopathological, and cognitive variables.
    de Bartolomeis A; Prinzivalli E; Callovini G; D'Ambrosio L; Altavilla B; Avagliano C; Iasevoli F
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():356-366. PubMed ID: 28887181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evaluation of functional capacity in treatment resistant schizophrenia patients: Comparison and differences with non-resistant schizophrenia patients.
    Iasevoli F; D'Ambrosio L; Notar Francesco D; Razzino E; Buonaguro EF; Giordano S; Patterson TL; de Bartolomeis A
    Schizophr Res; 2018 Dec; 202():217-225. PubMed ID: 29934250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses.
    de Bartolomeis A; Balletta R; Giordano S; Buonaguro EF; Latte G; Iasevoli F
    Psychiatry Res; 2013 Dec; 210(2):387-95. PubMed ID: 23910239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones.
    Iasevoli F; Giordano S; Balletta R; Latte G; Formato MV; Prinzivalli E; De Berardis D; Tomasetti C; de Bartolomeis A
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Feb; 65():34-48. PubMed ID: 26320028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
    Tollefson GD; Andersen SW
    J Clin Psychiatry; 1999; 60 Suppl 5():23-9; discussion 30. PubMed ID: 10192404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A symptom combination predicting treatment-resistant schizophrenia - A strategy for real-world clinical practice.
    Ortiz BB; Higuchi CH; Noto C; Joyce DW; Correll CU; Bressan RA; Gadelha A
    Schizophr Res; 2020 Apr; 218():195-200. PubMed ID: 31956005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia.
    Semiz UB; Cetin M; Basoglu C; Ebrinc S; Uzun O; Herken H; Balibey H; Algul A; Ates A
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1330-6. PubMed ID: 17618026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does early improvement predict response to the fast-dissociating D₂ receptor antagonist JNJ-37822681 in patients with acute schizophrenia?
    Anghelescu IG; Janssens L; Kent J; de Boer P; Tritsmans L; Daly EJ; van Nueten L; Schmidt ME
    Eur Neuropsychopharmacol; 2013 Sep; 23(9):1043-50. PubMed ID: 22995972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia.
    Meltzer HY; Lindenmayer JP; Kwentus J; Share DB; Johnson R; Jayathilake K
    Schizophr Res; 2014 Apr; 154(1-3):14-22. PubMed ID: 24630262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis.
    Kimura H; Kanahara N; Komatsu N; Ishige M; Muneoka K; Yoshimura M; Yamanaka H; Suzuki T; Komatsu H; Sasaki T; Hashimoto T; Hasegawa T; Shiina A; Ishikawa M; Sekine Y; Shiraishi T; Watanabe H; Shimizu E; Hashimoto K; Iyo M
    Schizophr Res; 2014 May; 155(1-3):52-8. PubMed ID: 24667073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of acute schizophrenia with paliperidone ER: predictors for treatment response and benzodiazepine use.
    Heres S; Don L; Herceg M; Bidzan L; Blanc M; Siracusano A; Maciulis V; Lahaye M; Schreiner A
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():207-12. PubMed ID: 24096139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation.
    Suzuki T; Remington G; Mulsant BH; Uchida H; Rajji TK; Graff-Guerrero A; Mimura M; Mamo DC
    Psychiatry Res; 2012 May; 197(1-2):1-6. PubMed ID: 22429484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes.
    Dunayevich E; Sethuraman G; Enerson M; Taylor CC; Lin D
    Schizophr Res; 2006 Sep; 86(1-3):300-8. PubMed ID: 16860974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The critical treatment window of clozapine in treatment-resistant schizophrenia: Secondary analysis of an observational study.
    Yoshimura B; Yada Y; So R; Takaki M; Yamada N
    Psychiatry Res; 2017 Apr; 250():65-70. PubMed ID: 28142068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia.
    Wehmeier PM; Kluge M; Schneider E; Schacht A; Wagner T; Schreiber W
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):703-12. PubMed ID: 17289237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of dopamine supersensitivity psychosis in treatment-resistant schizophrenia: An analysis of multi-factors predicting long-term prognosis.
    Yamanaka H; Kanahara N; Suzuki T; Takase M; Moriyama T; Watanabe H; Hirata T; Asano M; Iyo M
    Schizophr Res; 2016 Feb; 170(2-3):252-8. PubMed ID: 26775264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods.
    Chen L; Ascher-Svanum H; Stauffer V; Kinon BJ; Kollack-Walker S; Ruberg S
    Schizophr Res; 2009 Aug; 113(1):34-40. PubMed ID: 19564097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurological soft signs in first-episode schizophrenia: State- and trait-related relationships to psychopathology, cognition and antipsychotic medication effects.
    Emsley R; Chiliza B; Asmal L; Kilian S; Riaan Olivier M; Phahladira L; Ojagbemi A; Scheffler F; Carr J; Kidd M; Dazzan P
    Schizophr Res; 2017 Oct; 188():144-150. PubMed ID: 28130002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited.
    Ascher-Svanum H; Weiden P; Nyhuis AW; Faries DE; Stauffer V; Kollack-Walker S; Kinon BJ
    Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):84-90, 90A. PubMed ID: 23446198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.